# A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

> **NCT05123703** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 188 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab
- **OTHER:** Ocrelizumab Placebo
- **DRUG:** Fingolimod
- **OTHER:** Fingolimod Placebo

## Key facts

- **NCT ID:** NCT05123703
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-19
- **Primary completion:** 2025-06-09
- **Final completion:** 2029-09-17
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123703, "A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05123703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*